Neurokinin A and Matrix Metalloproteinase 9 Levels in Gingival Crevicular Fluid Samples of Teeth With Symptomatic Irreversible Pulpitis With Symptomatic Apical Periodontitis

Hadeer Mostafa El Mohamady El Feky

Status: Not yet enrolling

Conditions: Symptomatic Irreversible Pulpitis With Apical Peridontitis

Treatments: Diagnostic Test: Gingival crevicular fluid samples from the symptomatic teeth and the healthy contrlateral teeth

Study type: Observational

Funder types: Other

Identifiers

NCT07289074

Hadeer Mostafa -14422022580639

Details and patient eligibility

About

The aim of this study is to investigate the levels Neurokinin A and of Matrix Mtalloproteinase (MMP-9) in gingival crevicular fluid samples (GCF) as potential biomarkers for the diagnosis of symptomatic irreversible pulpitis with symptomatic apical periodontitis and to correlate the level of these diagnostic biomarkers ( Nerokinin A and MMP-9) with the pre-operative pain severity using the Numerical Rating Scale (NRS).

This study will utilize a comparative cross-sectional design to assess the levels of Neurokinin A (NKA) and Matrix metalloproteinase-9 (MMP-9) in gingival crevicular fluid (GCF) samples from symptomatic and healthy contralateral teeth with normal pulp.

Full description

The study design is Comparative Cross sectional study. The study will be conducted at the Dental hospital of Cairo University with access to patients undergoing treatment for teeth with pulpitis and apical periodontitis.

Enrollment: 23 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults (aged 18-60) diagnosed with symptomatic irreversible pulpitis with symptomatic apical periodontitis and have healthy contralateral teeth with normal pulp.
• The involved teeth should have healthy periodontal conditions (Normal periodontal pocket depth, No bleeding on Probing and No mobility).
• Patients who have not undergone any previous dental treatments in the involved teeth.
• Signed informed consent.

Exclusion criteria

• Patients with systemic diseases affecting the immune response (e.g., autoimmune diseases, uncontrolled diabetes).
• Patients taking medications that can affect the inflammatory markers (e.g., Steroids and Tetracyclins).
• Smokers.
• Individuals with periodontal disease unrelated to apical periodontitis.
• Presence of marginal bone loss.
• Pregnant women.

Trial design

23 participants in 2 patient groups

Patients diagnosed with symptomatic irreversible pulpitis with symptomatic apical peridontitis

Description:

* Gingival crevicular fluid samples will be collected from the symptomatic teeth and from the healthy contalateral teeth with normal pulp to detect the lavel of Neurokinin A (NKA) and Matrix metalloproteinase-9 (MMP-9) in the diseased teeth and compare it with that of the healthy teeth. * The study will also correlate the level of these biomarkers with the preoperative pain severity using the Numerical Rating Scale (NRS).

Treatment:

Diagnostic Test: Gingival crevicular fluid samples from the symptomatic teeth and the healthy contrlateral teeth

The healthy contralateral teeth of tha same patients

Description:

* Gingival crevicular fluid samples will be collected from the symptomatic teeth and from the healthy contalateral teeth to detect the lavel of Neurokinin A (NKA) and Matrix metalloproteinase-9 (MMP-9) in the diseased teeth and compare it with that of the healthy contralateral teeth. * The study will also correlate the level of these biomarkers and the preoperative pain severity using the Numerical Rating Scale (NRS).

Treatment:

Diagnostic Test: Gingival crevicular fluid samples from the symptomatic teeth and the healthy contrlateral teeth